Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mycophenolate Mofetil→

Mycophenolate Mofetil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
128794-94-5
Molecular formula
C23H31NO7
Molecular weight
433.5 g/mol
Drug class
Antimetabolite immunosuppressantprodrug of mycophenolic acid (MPA)
Mechanism of action
After absorption, mycophenolate mofetil is hydrolysed to mycophenolic acid, a selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This inhibits de-novo guanosine nucleotide synthesis and suppresses proliferation of T and B lymphocytes.
Indications / reported uses
  • Prophylaxis of organ rejection in adult and paediatric recipients aged 3 months and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants; not a stand-alone treatment for graft-versus-host disease or psoriasis

Sources: US DailyMed — Mycophenolate mofetil, updated 14 September 2026 · NLM DailyMed — Mycophenolate mofetil mechanism · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mycophenolate Mofetil Environmental Risk Assessment (ERA) (the Mycophenolate Mofetil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.